BMJ  2003;326:1427 (28 June), doi:10.1136/bmj.326.7404.1427

Paper

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

¹ Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and the London, Queen Mary's School of Medicine and Dentistry, University of London, London EC1M 6BQ

Objective To determine the average reduction in blood pressure, prevalence of adverse effects, and reduction in risk of stroke and ischaemic heart disease events produced by the five main categories of blood pressure lowering drugs according to dose, singly and in combination.

Design Meta-analysis of 354 randomised double blind placebo controlled trials of thiazides, blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, and calcium channel blockers in fixed dose.

Subjects 40 000 treated patients and 16 000 patients given placebo.

Main outcome measures Placebo adjusted reductions in systolic and diastolic blood pressure and prevalence of adverse effects, according to dose expressed as a multiple of the standard (recommended) doses of the drugs.

Results All five categories of drug produced similar reductions in blood pressure. The average reduction was 9.1 mm Hg systolic and 5.5 mm Hg diastolic at standard dose and 7.1 mm Hg systolic and 4.4 mm Hg diastolic (20% lower) at half standard dose. The drugs reduced blood pressure from all pretreatment levels, more so from higher levels; for a 10 mm Hg higher blood pressure the reduction was 1.0 mm Hg systolic and 1.1 mm Hg diastolic greater. The blood pressure lowering effects of different categories of drugs were additive. Symptoms attributable to thiazides, blockers, and calcium channel blockers were strongly dose related; symptoms caused by ACE inhibitors (mainly cough) were not dose related. Angiotensin II receptor antagonists caused no excess of symptoms. The prevalence of symptoms with two drugs in combination was less than additive. Adverse metabolic effects (such as changes in cholesterol or potassium) were negligible at half standard dose.

Conclusions Combination low dose drug treatment increases efficacy and reduces adverse effects. From the average blood pressure in people who have strokes (150/90 mm Hg) three drugs at half standard dose are estimated to lower blood pressure by 20 mm Hg systolic and 11 mm Hg diastolic and thereby reduce the risk of stroke by 63% and ischaemic heart disease events by 46% at age 60-69.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Authors’ reply

Malcolm Law, Joan K Morris, and Nicholas Wald
BMJ 2009 338: b2602. [Extract] [Full Text]

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

M R Law, J K Morris, and N J Wald
BMJ 2009 338: b1665. [Abstract] [Full Text] [PDF]

"Polypill" to fight cardiovascular disease: Authors' reply

Nicholas Wald, Malcolm Law, Joan Morris, Alicja Rudnicka, and Rachel Jordan
BMJ 2003 327: 809-810. [Extract] [Full Text]

A cure for cardiovascular disease?

Anthony Rodgers
BMJ 2003 326: 1407-1408. [Extract] [Full Text] [PDF]

The most important BMJ for 50 years?

Richard Smith
BMJ 2003 326: 0. [Extract] [Full Text] [PDF]

Pill could reduce cardiovascular disease considerably
BMJ 2003 326: 0. [Full Text] [PDF]

This article has been cited by other articles:

• Corp, E.V., Antoniou, S., Wright, P.G., Khachi, H., Vercaeren, S., Wald, D.S. (2009). Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals. QJM 0: hcp127v1-hcp127 [Abstract] [Full text]  
• Shantsila, A., Lip, G. Y H (2009). Review: combining 2 classes of blood pressure-lowering drugs has an approximately additive effect on systolic blood pressure. Evid. Based Med. 14: 142-142 [Full text]  
• Redon, J., Fabia, M. J. (2009). Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan. Journal of Renin-Angiotensin-Aldosterone System 10: 147-156 [Abstract]  
• Chobanian, A. V. (2009). The Hypertension Paradox -- More Uncontrolled Disease despite Improved Therapy. NEJM 361: 878-887 [Full text]  
• Kujala, U M (2009). Evidence on the effects of exercise therapy in the treatment of chronic disease. Br. J. Sports. Med. 43: 550-555 [Abstract] [Full text]  
• Putnam, W., Buhariwalla, F., Lacey, K., Goodfellow, M., Goodine, R. A., Hall, J., MacDonald, I., Murray, M., Smith, P., Burge, F., Natarajan, N., Lawson, B. (2009). Drug management for hypertension in type 2 diabetes in family practice. cfp 55: 728-734 [Abstract] [Full text]  
• Law, M., Morris, J. K, Wald, N. (2009). Authors' reply. BMJ 338: b2602-b2602 [Full text]  
• Law, M R, Morris, J K, Wald, N J (2009). Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665-b1665 [Abstract] [Full text]  
• Van der Niepen, P., Woestenburg, A., Brie, H., Vancayzeele, S., MacDonald, K., Denhaerynck, K., Lee, C., Hermans, C., Abraham, I. (2009). Effectiveness of Valsartan for Treatment of Hypertension: Patient Profiling and Hierarchical Modeling of Determinants and Outcomes (the PREVIEW Study). The Annals of Pharmacotherapy 43: 849-861 [Abstract] [Full text]  
• Bronson, D. L (2009). Review: less than maximum doses of ACE inhibitors lower BP to near maximum levels in hypertension. Evid. Based Med. 14: 49-49 [Full text]  
• Feldman, R. D., Zou, G. Y., Vandervoort, M. K., Wong, C. J., Nelson, S. A.E., Feagan, B. G. (2009). A Simplified Approach to the Treatment of Uncomplicated Hypertension: A Cluster Randomized, Controlled Trial. Hypertension 53: 646-653 [Abstract] [Full text]  
• Wu, Y., Huxley, R., Li, L., Anna, V., Xie, G., Yao, C., Woodward, M., Li, X., Chalmers, J., Gao, R., Kong, L., Yang, X., for the China NNHS Steering Committee and the Chin, (2008). Prevalence, Awareness, Treatment, and Control of Hypertension in China: Data from the China National Nutrition and Health Survey 2002. Circulation 118: 2679-2686 [Abstract] [Full text]  
• McLean, D. L., McAlister, F. A., Johnson, J. A., King, K. M., Makowsky, M. J., Jones, C. A., Tsuyuki, R. T., for the SCRIP-HTN Investigators, (2008). A Randomized Trial of the Effect of Community Pharmacist and Nurse Care on Improving Blood Pressure Management in Patients With Diabetes Mellitus: Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN). Arch Intern Med 168: 2355-2361 [Abstract] [Full text]  
• Dietz, R., Dechend, R., Yu, C.-M., Bheda, M., Ford, J., Prescott, M. F., Keefe, D. L. (2008). Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1. Journal of Renin-Angiotensin-Aldosterone System 9: 163-175 [Abstract]  
• Poulter, N. R. (2008). Selecting a fixed combination to improve morbidity/mortality: the weight of evidence with ASCOT. Eur Heart J Suppl 10: G21-G28 [Abstract] [Full text]  
• Chapman, N., Chang, C. L., Dahlof, B., Sever, P. S., Wedel, H., Poulter, N. R., on behalf of the ASCOT Investigators, (2008). Effect of Doxazosin Gastrointestinal Therapeutic System as Third-Line Antihypertensive Therapy on Blood Pressure and Lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 118: 42-48 [Abstract] [Full text]  
• Sudlow, C (2008). Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management. PN 8: 141-157 [Abstract] [Full text]  
• Bailey, K. R., Grossardt, B. R., Graves, J. W. (2008). Novel Use of Kaplan-Meier Methods to Explain Age and Gender Differences in Hypertension Control Rates. Hypertension 51: 841-847 [Abstract] [Full text]  
• Gojanovic, B., Feihl, F., Liaudet, L., Waeber, B. (2008). Review: Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. Journal of Renin-Angiotensin-Aldosterone System 9: 1-9 [Abstract]  
• Dietz, J. D., Du, S., Bolten, C. W., Payne, M. A., Xia, C., Blinn, J. R., Funder, J. W., Hu, X. (2008). A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity. Hypertension 51: 742-748 [Abstract] [Full text]  
• DeWilde, S, Carey, I M, Richards, N, Whincup, P H, Cook, D G (2008). Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment. Heart 94: 83-88 [Abstract] [Full text]  
• Wald, D. S, Morton, G., Walker, K., Iosson, N., Curzen, N. P (2007). Long-Term Continuation on Cardiovascular Drug Treatment in Patients with Coronary Heart Disease. The Annals of Pharmacotherapy 41: 1644-1647 [Abstract] [Full text]  
• Chobanian, A. V. (2007). Isolated Systolic Hypertension in the Elderly. NEJM 357: 789-796 [Full text]  
• Hood, S. J., Taylor, K. P., Ashby, M. J., Brown, M. J. (2007). The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin Hypertension and Elevated Aldosterone-Renin Ratio. Circulation 116: 268-275 [Abstract] [Full text]  
• Authors/Task Force Members:, , Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R. E., Struijker Boudier, H. A.J., Zanchetti, A., ESC Committee for Practice Guidelines (CPG):, , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., ESH Scientific Council:, , Kjeldsen, S. E., Erdine, S., Narkiewicz, K., Kiowski, W., Agabiti-Rosei, E., Ambrosioni, E., Cifkova, R., Dominiczak, A., Fagard, R., Heagerty, A. M., Laurent, S., Lindholm, L. H., Mancia, G., Manolis, A., Nilsson, P. M., Redon, J., Schmieder, R. E., Struijker-Boudier, H. A.J., Viigimaa, M., Document Reviewers:, , Filippatos, G., Adamopoulos, S., Agabiti-Rosei, E., Ambrosioni, E., Bertomeu, V., Clement, D., Erdine, S., Farsang, C., Gaita, D., Kiowski, W., Lip, G., Mallion, J.-M., Manolis, A. J., Nilsson, P. M., O'Brien, E., Ponikowski, P., Redon, J., Ruschitzka, F., Tamargo, J., van Zwieten, P., Viigimaa, M., Waeber, B., Williams, B., Zamorano, J. L. (2007). 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 0: ehm236v1-75 [Full text]  
• Chapman, N., Dobson, J., Wilson, S., Dahlof, B., Sever, P. S., Wedel, H., Poulter, N. R., on behalf of the Anglo-Scandinavian Cardiac Outcom, (2007). Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension. Hypertension 49: 839-845 [Abstract] [Full text]  
• Mahmud, A., Feely, J. (2007). Low-Dose Quadruple Antihypertensive Combination: More Efficacious Than Individual Agents-A Preliminary Report. Hypertension 49: 272-275 [Abstract] [Full text]  
• Reid, J. L. (2007). Fall and Rise of Polypharmacy?. Hypertension 49: 266-267 [Full text]  
• Rasmussen, J. N., Chong, A., Alter, D. A. (2007). Relationship Between Adherence to Evidence-Based Pharmacotherapy and Long-term Mortality After Acute Myocardial Infarction. JAMA 297: 177-186 [Abstract] [Full text]  
• Ong, K. L., Cheung, B. M.Y., Man, Y. B., Lau, C. P., Lam, K. S.L. (2007). Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999-2004. Hypertension 49: 69-75 [Abstract] [Full text]  
• Ma, J., Lee, K.-V., Stafford, R. S. (2006). Changes in Antihypertensive Prescribing During US Outpatient Visits for Uncomplicated Hypertension Between 1993 and 2004. Hypertension 48: 846-852 [Abstract] [Full text]  
• O'Kennedy, N., Crosbie, L., Whelan, S., Luther, V., Horgan, G., Broom, J. I, Webb, D. J, Duttaroy, A. K (2006). Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans.. Am. J. Clin. Nutr. 84: 561-569 [Abstract] [Full text]  
• Kotchen, T. A. (2006). From Clinical Trials to Clinical Practice: Why the Gap?. Hypertension 48: 196-197 [Full text]  
• Sleight, P., Pouleur, H., Zannad, F. (2006). Benefits, challenges, and registerability of the polypill. Eur Heart J 27: 1651-1656 [Abstract] [Full text]  
• Dobesh, P. P. (2006). Managing hypertension in patients with type 2 diabetes mellitus.. Am J Health Syst Pharm 63: 1140-1149 [Abstract] [Full text]  
• Zillich, A. J., Haines, S. T. (2006). ASHP Therapeutic Position Statement on the Treatment of Hypertension.. Am J Health Syst Pharm 63: 1074-1080 [Full text]  
• Poulter, N. (2006). Are current therapies for hypertension achieving their goal?. Journal of Renin-Angiotensin-Aldosterone System 7: S3-S6 [Abstract]  
• Ovbiagele, B., Hills, N. K., Saver, J. L., Johnston, S. C., for the CASPR Investigators, (2006). Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA. Neurology 66: 313-318 [Abstract] [Full text]  
• Gu, Q., Paulose-Ram, R., Dillon, C., Burt, V. (2006). Antihypertensive Medication Use Among US Adults With Hypertension. Circulation 113: 213-221 [Abstract] [Full text]  
• Andersson, K., Melander, A., Svensson, C., Lind, O., Nilsson, J. L. G. (2005). Repeat prescriptions: refill adherence in relation to patient and prescriber characteristics, reimbursement level and type of medication. Eur J Public Health 15: 621-626 [Abstract] [Full text]  
• Combination Pharmacotherapy and Public Health Rese, (2005). Combination Pharmacotherapy for Cardiovascular Disease. ANN INTERN MED 143: 593-599 [Abstract] [Full text]  
• Khan, N. A., Hamet, P., Lewanczuk, R. Z., For the Canadian Hypertension Education Program, (2005). Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension. CMAJ 173: 865-867 [Full text]  
• Law, M., Morris, J. K., Jordan, R., Wald, N. (2005). Headaches and the Treatment of Blood Pressure: Results From a Meta-Analysis of 94 Randomized Placebo-Controlled Trials With 24 000 Participants. Circulation 112: 2301-2306 [Abstract] [Full text]  
• Ovbiagele, B., Hills, N. K., Saver, J. L., Johnston, S. C. (2005). Antihypertensive Medications Prescribed at Discharge After an Acute Ischemic Cerebrovascular Event. Stroke 36: 1944-1947 [Abstract] [Full text]  
• Chapman, R. H., Benner, J. S., Petrilla, A. A., Tierce, J. C., Collins, S. R., Battleman, D. S., Schwartz, J. S. (2005). Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy. Arch Intern Med 165: 1147-1152 [Abstract] [Full text]  
• Vasan, R. S., Sullivan, L. M., Wilson, P. W.F., Sempos, C. T., Sundstrom, J., Kannel, W. B., Levy, D., D'Agostino, R. B. (2005). Relative Importance of Borderline and Elevated Levels of Coronary Heart Disease Risk Factors. ANN INTERN MED 142: 393-402 [Abstract] [Full text]  
• Petrie, J. R, Kirby, M. (2004). Too much of a good thing: 2004 guidance from NICE and BHS-IV on hypertension in diabetes. British Journal of Diabetes & Vascular Disease 4: 365-368  
• Jarvis, S. C (2004). VALUE, blood pressure and diabetes -- what can we learn?. British Journal of Diabetes & Vascular Disease 4: 418-420 [Abstract]  
• Narayan, K.M. V. (2004). "Polypill" for Cardiovascular Disease Prevention. Clin. Diabetes 22: 157-158 [Abstract] [Full text]  
• Boutitie, F., Lawes, C. M.M., Bennett, D. A., Feigin, V. L., Rodgers, A. (2004). Relationship Between Stroke Relative Risk and Change in Systolic Blood Pressure: The Misuse of Meta-Regression * Response. Stroke 35: 2237-2238 [Full text]  
• Kroenke, K., Logio, L. (2004). Update in General Internal Medicine. ANN INTERN MED 141: 213-220 [Full text]  
• Emberson, J., Whincup, P., Morris, R., Walker, M., Ebrahim, S. (2004). Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 25: 484-491 [Abstract] [Full text]  
• Linden, W. (2004). Review: lower dose combination antihypertensive therapy is preferable to standard dose single drug therapy. Evid. Based Med. 9: 11-11 [Full text]  
• Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L. Jr, Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T. Jr, Roccella, E. J., the National High Blood Pressure Education Program, (2003). Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252 [Abstract] [Full text]  
• Marshall, T. (2003). Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ 327: 1264- [Abstract] [Full text]  
• Wald, N., Law, M., Morris, J., Rudnicka, A., Jordan, R. (2003). "Polypill" to fight cardiovascular disease: Authors' reply. BMJ 327: 809-810 [Full text]  
• Malik, I. (2003). JournalScan. Heart 89: 1119-1120 [Full text]  
• (2003). A Pollypill for Everything (Cardiovascular)?. JWatch Gastroenterology 2003: 6-6 [Full text]  
• (2003). Theoretical Combination Pill for Cardiovascular Risk Reduction. Journal Watch Cardiology 2003: 3-3 [Full text]  
• (2003). A Polypill for Everything (Cardiovascular)?. JWatch General 2003: 2-2 [Full text]  
• Wald, N J, Law, M R (2003). A strategy to reduce cardiovascular disease by more than 80%. BMJ 326: 1419- [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

Err... where's the clinical trial?

Douglas J Carnall
bmj.com, 27 Jun 2003 [Full text]

Caution

Gert Martin Kaiser
bmj.com, 2 Jul 2003 [Full text]

Balancing efficacy and side effects in hypertensive treatment

Adrian G Stanley, et al.
bmj.com, 3 Jul 2003 [Full text]

Online poll

Find out more >>